Franchise winners prove that not only big is beautiful
This article was originally published in Clinica
The past year proved to be volatile and difficult for US medical device stocks, with only large capitalisation companies performing particularly well. Carol Winslow takes a close look at developments and assesses the factors that will shape the market in 1998.
You may also be interested in...
The US is to ship only half of doses for Pfizer, Moderna COVID-19 vaccines in the first instance, while Rhizen Pharmaceuticals starts a Phase I trial of a DHODH inhibitor.
Given its ever-growing role as a critical component of the global biopharma industry, you can’t afford not to be up to speed on Asia. This biweekly selection of insights from our experienced on-the-ground team will help.
Becton Dickinson will spend $1.2bn over the next four years to improve its drug-delivery device manufacturing capabilities. See what Eric Borin, president of BD, said about it here.